Come Visit Us at ASGCT 2021 and Enjoy Our Posters Co-Authored with Pall Biotech
We’re excited to be exhibiting at this year’s ASGCT annual meeting. Please stop by and learn what’s new in the world of Blood-Free components and media. And, don’t forget to take a look at our poster about Aber Biomass Probes’ utility with Chemically Defined iCELLis-Based Viral Vector Manufacturing.
Emergence of a Blood-Free rHSA
Blood-Free rHSA will add safety, consistency, and enhanced performance to your cell culturing processes.
Our new Featured Report explores the many benefits of albumin and the various challenges that serum-derived proteins can create. Recombinant human serum albumin (rHSA), and specifically InVitria’s Blood-Free rHSA, overcomes these challenges, enhances performance, and is preferred by regulatory agencies.
The global leader in the production of blood-free components, supplements, and media to facilitate the approval of life changing medicines.
InVitria’s portfolio of chemically defined blood-free products enables development and production of novel therapeutics without use of any blood-derived components.
Click on the application of interest to find out how our products set the new standards in biologics manufacturing.
InVitria offers a suite of recombinant protein products, each of which is completely free of animal or human components and produced in a scalable, non-mammalian recombinant expression system at an ISO9001:2015 certified facility in Kansas, USA.
InVitria is the leading brand of custom media formulations for gene therapy, cell therapy, vaccine & antibody production, and related culturing applications. Contact us to discuss your cell culture needs. Let us do the heavy lifting!
- Blood-Free & Chemically Defined
- High Performance
- Reliable Supply Chain
- Faster Time to Market
Select the cell line or an application of interest and discover more information relevant to your work.
- Decreased variability in cell culture media.
- Accelerated gene therapy research.
- Improved scalability & increased speed of gene therapy manufacturing.
- Reduced cost in time and resources for manufacturing.